A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy, in advanced ovarian carcinoma

• Published in: Cancer research (Chicago, Ill.) Ill.), 1996-02, Vol.56 (4), p.689-693
• Main Authors: RIGHETTI, S. C, DELLA TORRE, G, BÖHM, S, BRESCIANI, G. L, SPATTI, G, ZUNINO, F, PILOTTI, S, MENARD, S, OTTONE, F, COLNAGHI, M. L, PIEROTTI, M. A, LAVARINO, C, CORNAROTTI, M, ORIANA, S
• Format: Article
• Language: English
• Subjects: Alleles; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Cisplatin - therapeutic use; Codon; Exons; Female; General aspects; Genes, p53; Humans; Immunohistochemistry; Immunophenotyping; Introns; Medical sciences; Middle Aged; Neoplasm Staging; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - genetics; Ovarian Neoplasms - pathology; Ovarian Neoplasms - surgery; Pharmacology. Drug treatments; Point Mutation; Sequence Deletion; Tumor Suppressor Protein p53 - biosynthesis
• ISSN: 0008-5472; 1538-7445

The p53 protein is a multifunctional transcriptional regulator involved in cellular response to DNA damage and has been implicated as a putative determinant of sensitivity of tumor cells to cytotoxic agents. Since the p53 gene becomes inactivated in over one-half of advanced ovarian carcinoma, in this study we have examined the relationships between p53 gene alterations, p53 immunoreactivity, and response to cisplatin-based chemotherapy in ovarian cancer patients. All patients had advanced (FIGO stage III or IV) ovarian carcinoma and, with one exception, were untreated at the time of collection of tumor specimens. After initial debulking surgery, patients received high-dose cisplatin therapy. Tumor samples were analyzed for p53 gene mutations and for p53 protein accumulation, and the findings were correlated with tumor responsiveness. Of the 33 tumors examined, p53 gene mutations were found in 20 cases, including 15 missense mutations, 2 deletions, 2 nonsense mutations, and a base substitution at splice site. Twenty tumors showed positive immunostaining for p53. Only missense mutations were associated with positive immunostaining. In addition, p53 overexpression was detected in five tumors in the absence of mutations. Most (12 of 14) of the missense mutations associated with p53 protein stabilization were found refractory to therapy, as well as tumors overexpressing wild-type p53 (4 of 5). A significant correlation has been found between p53 accumulation, type of mutation (i.e., missense mutations), and pathological response to cisplatin-based therapy. In conclusion, the present results are consistent with a role of p53 as a determinant of chemosensitivity of ovarian carcinoma.